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Background: McCune-Albright Syndrome (MAS) is usually characterized by the triad of precocious puberty (PP),
fibrous dysplasia, and café au lait spots. Previous treatments investigated for PP have included aromatase inhibitors
and the estrogen receptor modulator, tamoxifen. Although some agents have been partially effective, the optimal
pharmacologic treatment of PP in girls with MAS has not been identified. The objective of this study was to
evaluate the safety and efficacy of fulvestrant (FaslodexTM), a pure estrogen receptor antagonist, in girls with
progressive precocious puberty (PP) associated with McCune-Albright Syndrome (MAS).
Methods: In this prospective international multicenter trial, thirty girls≤ 10 years old with MAS and progressive
PP received fulvestrant 4 mg/kg via monthly intramuscular injections for 12 months. Changes in vaginal bleeding,
rates of bone age advancement, growth velocity, Tanner staging, predicted adult heights, and uterine and ovarian
volumes were measured.
Results: Median vaginal bleeding days decreased from 12.0 days per year to 1.0 day per year, with a median
change in frequency of -3.6 days, (95% confidence interval (CI) -10.10, 0.00; p = 0.0146). Of patients with baseline
bleeding, 74% experienced a ≥50% reduction in bleeding, and 35% experienced complete cessation during the
study period (95% CI 51.6%, 89.8%; 16.4%, 57.3%, respectively). Average rates of bone age advancement (ΔBA/ΔCA)
decreased from 1.99 pre-treatment to 1.06 on treatment (mean change -0.93, 95% CI -1.43, -0.43; p = 0.0007). No
significant changes in uterine volumes or other endpoints or serious adverse events occurred.
Conclusions: Fulvestrant was well tolerated and moderately effective in decreasing vaginal bleeding and rates of
skeletal maturation in girls with MAS. Longer-term studies aimed at further defining potential benefits and risks of
this novel therapeutic approach in girls with MAS are needed.
Trial registration: NCT00278915
Keywords: McCune Albright syndrome, Peripheral precocious puberty, Estrogen receptor antagonistBackground
McCune-Albright syndrome (MAS) is characterized by
the triad of peripheral precocious puberty (PP), fibrous
dysplasia of bone, and café au lait spots [1,2]. This dis-
order develops secondary to a post-zygotic gain of func-
tion mutation in the gene encoding the alpha subunit of
the heterotrimeric G-protein (Gsα) on chromosome 20,
resulting in constitutive activation in affected cells [3,4].* Correspondence: eksims@iupui.edu
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reproduction in any medium, provided the orPP, the most common manifestation of MAS, is diag-
nosed more frequently in girls than boys [5]. Autono-
mous activation of ovarian tissue leads to intermittent
development of ovarian cysts, resulting in vaginal bleed-
ing upon resolution and subsequent estrogen withdrawal
[5,6]. A subset of girls develop progressive PP marked by
recurrent vaginal bleeding, increased breast develop-
ment, accelerated growth velocity, and bone age (BA)
advancement with the potential for significant com-
promise in adult height [5]. Although the PP in MAS is
gonadotropin independent, secondary activation of the
hypothalamic-pituitary-gonadal axis may occur, resulting
in concurrent central precocious puberty (CPP) [7].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have met with mixed success. Fulvestrant (FaslodexTM)
is a pure antiestrogen that binds to the estrogen recep-
tor, triggering rapid degradation [8]. The objective of our
study was to evaluate the safety and efficacy of fulves-
trant in girls with progressive PP associated with MAS.
Methods
This international prospective open-label trial recruited
girls from 15 centers and was approved by an Institu-
tional Review Board at each site. Because of the rarity of
MAS, a study based on formal power calculations was
not feasible. However, based on a similar AstraZeneca
study evaluating tamoxifen in this population, an
assumed proportion of 0.67 patients with a ≥ 50% reduc-
tion in vaginal episodes was used to determine that a
group of 20 patients would generate a 95% confidence
interval (CI) of 0.46-0.87 [9]. Thus, 30 patients were
recruited with the goal of having 20 patients complete
12 months of treatment. Inclusion criteria included
age ≤ 10 years at the start of therapy, and a diagnosis of
MAS and progressive PP (onset before 8 years of age)
made by a pediatric endocrinologist. MAS was diag-
nosed based on the presence of PP combined with café
au lait spots, fibrous dysplasia, or a documented Gsα
mutation. Subjects had clinical evidence of pubertal pro-
gression along with BA advancement (BA ≥ 12 months
above chronologic age) or growth velocity > 2 standard
deviations (SD) above the mean for age. Previously trea-
ted patients must have had documented progression on
treatment with a 1 month washout period, or have
stopped treatment for 6 months with subsequent pro-
gression of disease. Patients with CPP must have
received at least 6 months of treatment with a
gonadotropin-releasing hormone analog (GnRHa). Writ-
ten informed consent of all parents/legal guardians and
patient assent as locally required was obtained.
Patients were excluded if they had previously received
fulvestrant, were currently receiving treatment for periph-
eral PP, had liver function tests ≥ 3 times the upper limit
of normal, an International Normalized Ratio (INR) > 1.6,
a history of bleeding diathesis or long-term anticoagula-
tion, any severe comorbidities, or known hypersensitivity
to any component of the study drug product.
Initial assessment occurred at a screening visit, fol-
lowed by 13 monthly visits. Six months of pre-treatment
data, including height, weight, Tanner stage, BA, and
parental recall of vaginal bleeding history, were retro-
spectively reviewed. Physical exam including Tanner sta-
ging for breasts and pubic hair was performed at
screening and at the 0, 3, 6, and 12 month visits.
BA radiographs were obtained at baseline, 6 and
12 months. Rate of skeletal maturation was defined as
the change in BA divided by the change in chronologicalage. Pre-treatment BAs obtained at a minimum of 6 and
maximum of 15 months apart were used to determine
pre-treatment rates of skeletal maturation. Predicted
adult heights (PAHs) were calculated based on the
method of Bayley and Pinneau for patients 6 years or
older. Vaginal bleeding data were obtained from patient
diaries and reviewed monthly. Any missing days on diary
cards were reported as bleeding days. Pelvic ultrasounds
were obtained at the screening, 6 month, and 12 month
visits. All radiographs were centrally read at Lifespan
Health Research Center, at Wright State University, in
Kettering, Ohio and all ultrasounds were read at Bio
Clinica Inc., in Newton, Pennsylvania. Radiologists were
blinded to patient diagnosis.
Chemiluminescent serum estradiol, testosterone, lu-
teinizing hormone (LH), and follicle stimulating hor-
mone (FSH) assays were obtained at screening and at 3,
6, and 12 months. Thyroxine and thyrotropin levels were
drawn at baseline. Complete blood count, INR, alanine
aminotransferase, and aspartate transaminase levels were
obtained during screening. Liver function tests were
repeated at the last visit. Laboratory assays were
performed by Quintiles Laboratories North America
(Marietta, GA).
The dose of fulvestrant was derived from studies in
breast cancer patients, and was initiated at 2 mg/kg via
monthly intramuscular injections in the first 10 patients
[10]. Based on pharmacokinetics from the first 6
patients, the dose was increased to 4 mg/kg injections
monthly, which corresponds to a dose of 250 mg/month
in adult patients. All remaining patients received this
dose for the entire study period. At 2 different time
points between the 6 and 12 month visits, serum trough
levels of medication were obtained to ensure that steady
state drug concentrations were similar to those of
patients in the breast cancer studies. Participants who
completed the study were offered the option of continu-
ing on treatment for an extension period with yearly
data collection.
Intention-to-treat as well as per-protocol statistical
analyses were performed. Results from both evaluations
were consistent and so outcomes of the intention-to-
treat analysis are reported. Analysis of hormone changes
was performed retrospectively. For continuous efficacy
endpoints with normal distributions, the mean changes
from baseline to the treatment period were analyzed
using the 2-sided paired t-test at the 5% level of signifi-
cance, with a 95% CI using SAS PROC MEANS.
A Signed rank test or a Sign test was used to analyze me-
dian changes (with SAS PROC UNIVARIATE) for end-
points with non-normal distributions. A distribution-free
95% CI of the median was obtained using SAS PROC
UNIVARIATE with CIPCTLDF option. To evaluate the
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Figure 1 Change in frequency of annualized days of vaginal
bleeding from pre-treatment to on- treatment period. Bleeding
was calculated based on worst-case scenario (assuming bleeding
occurred on days without diary data available). *Patients with one or
more missing days of data which were counted as bleeding days.
†Patients withdrew from study due to worsening of condition.Results
A total of 30 girls aged 5.86 ± 1.8 years were enrolled, of
whom 29 completed 12 months of treatment. All patients
had at least 2 of the classic components of MAS, and all
had evidence of progressive PP. Three girls were receiv-
ing a GnRHa at baseline. Four girls had received aroma-
tase inhibitors in the past, and none had been treated
with tamoxifen. Twenty-three (77%) had vaginal bleeding
during the pre-study interval. Baseline as well as pre-
treatment participant characteristics are provided in
Table 1.
Pharmacokinetic data revealed that patients on the
4 mg/kg dose reached steady-state serum concentrations
consistent with patients effectively treated with fulves-
trant for breast cancer. The mean serum half-life of the
drug was 70.4 ± 8.1 days.
Median vaginal bleeding days on treatment decreased
from 12.0 days per year to 1.0 day per year, with a median
change in frequency of -3.6 days (p = 0.0146). Of the
patients with baseline bleeding, 17 (74%) experienced a
≥50% reduction in bleeding, and 8 (35%) experienced
complete cessation during the year of study (CI 51.6%,
89.8%; 16.4%, 57.3%, respectively). One patient was with-
drawn due to worsening of her condition after receiving
6 injections. Figure 1 depicts individual changes in vagi-
nal bleeding.
Average rates of BA advancement decreased from 1.99
at baseline to 1.06 after 12 months of treatment, a differ-
ence of 0.93 ± 1.3 (95% CI -1.43, -0.43; p = 0.0007), whenTable 1 Baseline patient demographics (n = 30)







Polyostotic fibrous dysplasia (n) 21 (70.0%)
Café au lait spots (n) 24 (80.0%)
Confirmed Gsα mutation (n) 7 (23.3%)
Vaginal bleeding during 6 months
pre-treatment (n)
23 (76.7%)
Median Tanner Stage for breasts (range) III (I-IV)
Median Tanner Stage for pubic hair (range) I (I-IV)
Mean growth velocity Z-score ± SD during
6 months prior to study
2.35 ± 3.3
SD-standard deviation.compared with the pre-treatment interval. Furthermore,
this was progressive, as the mean BA advancement over
the first 6 months of treatment decreased by 0.83 com-
pared to pretreatment (95% CI -1.39, -0.26; p =0.005),
while over the second 6 months, a more substantial de-
crease of 1.10 was seen (95% CI -1.63, -0.58; p = 0.0002).
Individual changes in skeletal maturation are illustrated
in Figure 2. No statistically significant difference was
seen in mean growth velocity z-scores during treatment
compared with the pre-treatment interval (mean change
-1.14, 95% CI -2.67, 0.38; p = 0.135). Mean PAHs before
and after treatment were equivalent (163.0 ± 6.9 cm vs.
163.5 ± 6.3 cm).
Hormone levels are presented in Table 2. Patients
experienced a significant decrease in LH on treatment,
with a median difference of 0.35 IU/L from baseline to
12 months (CI 0, 0.8; p < 0.005). No girls developed CPP
during the study period. Mean uterine volume at base-
line was 8.2 ± 5.0 ml, corresponding to a pubertal size.
No significant difference was seen in uterine size during
the 12 months of study. No significant changes in other
hormones, Tanner staging, ovarian cysts, or ovarian
volumes were seen throughout the study period.
Fulvestrant was generally well tolerated. Seven patients
reported injection site reactions that were typically short
lived, but recurred in over half of cases. These included
mild hematoma and rash as well as mild-moderate in-
flammation. Vomiting and abdominal pain possibly
related to fulvestrant were each reported in 1 patient.
















Pre-treatment Period On-treatment Period
Figure 2 Change in skeletal maturation. Rate of skeletal
maturation during pre-treatment (change in BA during 6 months
prior to treatment) and on-treatment period (change in BA during
the 12 months of study) by patient (n = 30).
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verse events. Of the 29 patients completing the study, 24
girls chose to enter the extension phase and continue
treatment.
Discussion
The ideal treatment of PP in girls with MAS remains
elusive. Medroxyprogesterone and cyproterone acetate
can be effective for alleviation of vaginal bleeding, but
have no effect on BA advancement [11,12]. Ketoconazole
has been reported to result in cessation of bleeding and
regression of secondary sexual characteristics in case
studies, but lack of long-term data and concerns for riskTable 2 Mean hormone levels
Hormone (units) Visit n Mean± SD Median
Free thyroxine (pmol/L) Screening 30 14.42 ± 2.53 14.65
Thyrotropin (mIU/L) Screening 30 2.38 ± 3.30 1.53
Estradiol (pmol/L) Screening 30 20.54 ± 25.59 9.18
6 month visit 29 36.10 ± 104.95 9.18
12 month visit 26 25.95 ± 30.72 9.55
LH (IU/L)* Screening 30 0.84 ± 1.04 0.45
6 month visit 29 0.10 ± 0.02 0.10
12 month visit 28 0.11 ± 0.04 0.10
FSH (IU/L) Screening 30 3.86 ± 5.42 1.95
6 month visit 29 0.82 ± 0.78 0.50
12 month visit 29 1.13 ± 1.02 0.60
Testosterone (nmol/L) Screening 30 0.53 ± 0.19 0.48
6 month visit 29 0.56 ± 0.24 0.45
12 month visit 28 0.65 ± 0.27 0.66
Prepubertal normal ranges: free thyroxine 10.3-25.7 pmol/L; thyrotropin 0.7-6.4
mIU/L; estradiol < 73.4 pmol/L; LH 0.6-1.6 IU/L; FSH 0.7-6.7 IU/L;
testosterone < 0.35-1.2 nmol/L.
* P < 0.005 for median change from baseline to month 12.of adrenal insufficiency and hepatotoxicity have limited
its use. Thus, recent interest has revolved around the
use of antiestrogens [13-15].
Aromatase inhibitors (AIs) function by binding to the
cytochrome P450 portion of aromatase, inhibiting the
conversion of androgens to estrogens [16]. While this
class of drugs initially showed promise in MAS, long-
term studies of the first generation AI testolactone
revealed no significant improvement in skeletal matur-
ation [16-18]. Later generation agents with increased
potency have similarly failed to indicate significant bene-
fit in prospective trials, with the exception of letrozole
[19-21]. While this third generation AI did have a posi-
tive effect on indices of PP in a small study, an increase
in mean ovarian volumes and occurrence of ovarian tor-
sion in one patient have raised concerns regarding the
safety of this drug [21].
Tamoxifen, a selective estrogen receptor modulator
widely used in breast cancer therapy, binds to the es-
trogen receptor and only partially triggers the normal
activating sequence, thereby attenuating transcription
[8]. While a prospective study of this medication in
girls with MAS and PP demonstrated decreases in va-
ginal bleeding, growth velocities, and skeletal matur-
ation, a progressive increase in uterine volume was
observed during the treatment period [9]. Although
the significance of this finding remains unknown, it is
of concern given previous links to endometrial stromal
tumor development in women undergoing tamoxifen
therapy [22].
Fulvestrant was also developed as a treatment for
breast cancer subsequent to its effects at the level of the
estrogen receptor. Because of its purely antagonistic
properties, the partial estrogen agonistic actions seen
with tamoxifen should hypothetically be avoided [8].
This was supported by lack in changes in uterine or
ovarian dimensions on treatment. To our knowledge, no
previous reports utilizing fulvestrant in pediatric patients
exist. This study demonstrated that fulvestrant signifi-
cantly decreased vaginal bleeding and reduced rates of
skeletal maturation to near normal in this population.
However, complete cessation of vaginal bleeding oc-
curred in only a third of subjects, and no significant
change in growth velocity or PAH was seen. A progres-
sive decrease in BA advancement with drug exposure
supports that a longer treatment interval might improve
these parameters. The etiology for the observed decrease
in LH levels is unclear, but may have been temporally
related to episodic autonomous ovarian activation, which
would not be expected to be altered by fulvestrant.
There are several limitations to our study. Because of the
rarity of MAS, each girl served as her own control. How-
ever, the inclusion of multiple centers enabled a reasonable
sample size and generated statistically significant results. A
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missing data for vaginal bleeding diaries that could
potentially underestimate the benefits of treatment. Pre-
treatment vaginal bleeding data was collected retrospect-
ively and therefore may not have been as accurate as data
collected during the treatment period. Conversely, concur-
rent MAS-related endocrinopathies and skeletal deform-
ities resulting from fibrous dysplasia could have affected
growth velocities, rates of skeletal maturation, and accuracy
of height measurements. The lack of change in growth vel-
ocities and PAH could reflect an insufficient treatment
interval or other aspects of MAS unrelated to PP.
Conclusion
In conclusion, fulvestrant was moderately effective in de-
creasing vaginal bleeding and rates of skeletal matur-
ation in girls with progressive PP secondary to MAS
over a 1 year period. The medication was well tolerated.
Longer follow-up of patients receiving treatment will be
necessary in order to confirm these results.
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